Chunyu Tian, Xiujun Peng, Zhengjun Fan, Xia Zhang, Feihu Zhou
General Navy Hospital Eye Department, #6 Fucheng Road, Beijing, China, 100048.
PLA General Hospital Intensive Care Center, #28 Fuxing Road, Beijing, China, 100853.
Sci Rep. 2014 Jul 10;4:5652. doi: 10.1038/srep05652.
The aim of this study was to determine the effectiveness of corneal collagen cross-linking (CXL) for the treatment of progressive keratoconus (KC). Some of the published literature, including a few small, randomized controlled trials (RCTs), demonstrated good results after CXL, but large RCTs with long-term follow-up to establish a cause-effect relationship are lacking. Using PubMed, EMBASE, and the Cochrane Library database, we searched for relevant studies published between October 2007 and March 2014. A comprehensive literature search was performed using the Cochrane Collaboration methodology to identify the effectiveness of CXL for treating KC. The primary outcome parameters included uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), refraction, corneal topography, and corneal thickness at baseline and at 1, 3, 6, 12, and 18 months after CXL. A total of 1171 participants (1557 eyes) were enrolled in this meta-analysis. CXL may be effective in halting the progress of KC for at least 12 months under certain conditions. However, further research from randomized trials is needed to confirm our findings.
本研究的目的是确定角膜胶原交联（CXL）治疗进行性圆锥角膜（KC）的有效性。一些已发表的文献，包括一些小型随机对照试验（RCT），显示CXL术后效果良好，但缺乏长期随访以建立因果关系的大型RCT。我们使用PubMed、EMBASE和Cochrane图书馆数据库，检索了2007年10月至2014年3月期间发表的相关研究。采用Cochrane协作方法进行全面的文献检索，以确定CXL治疗KC的有效性。主要结局参数包括基线时以及CXL后1、3、6、12和18个月时的裸眼视力（UCVA）、最佳矫正视力（BCVA）、屈光、角膜地形图和角膜厚度。本荟萃分析共纳入1171名参与者（1557只眼）。在某些条件下，CXL可能有效地阻止KC进展至少12个月。然而，需要随机试验的进一步研究来证实我们的发现。
